U.S. Capital Markets Stock News

Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication. This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy. We'll explore how Fast Track status for AlloNK and...

Key Insights Significantly high institutional ownership implies Vir Biotechnology's stock price is sensitive to their...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

With a price-to-earnings (or "P/E") ratio of 7x Dream Finders Homes, Inc. ( NYSE:DFH ) may be sending very bullish...

Nordic American Tankers (NYSE:NAT) has had a great run on the share market with its stock up by a significant 27% over...

As the Dow Jones Industrial Average reaches an all-time high amidst a flurry of corporate earnings reports, investors are keenly observing the broader U.S. market's performance against a backdrop of ongoing government shutdown and trade discussions with China. In this environment, identifying undervalued stocks becomes crucial for those looking to capitalize on potential opportunities that may arise from discrepancies between current stock prices and their intrinsic value.

Most readers would already be aware that Teekay's (NYSE:TK) stock increased significantly by 11% over the past three...

As the Dow Jones Industrial Average reaches an all-time high amid a flurry of robust earnings reports, the broader U.S. market is experiencing a wave of optimism despite ongoing economic challenges such as the government shutdown. In this environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding, especially as investors look beyond well-known names to uncover hidden opportunities within the market.

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

United States Lime & Minerals, Inc.'s ( NASDAQ:USLM ) price-to-earnings (or "P/E") ratio of 30.9x might make it look...

If you have been eyeing Regal Rexnord and wondering, “What should I do next?” you are not alone. Investors are trying to navigate the waters after seeing the stock trade at $145.04 most recently, with a modest 1.3% gain over the past week and a 1.1% uptick for the past month. Still, Regal Rexnord’s longer-term chart tells a more mixed story: shares are down 5.4% year-to-date and off 13.7% from where they stood a year ago. Those who have held on for five years are sitting on a 69.1%...

We can readily understand why investors are attracted to unprofitable companies. For example, Palladyne AI...

With a price-to-earnings (or "P/E") ratio of 4.2x MV Oil Trust ( NYSE:MVO ) may be sending very bullish signals at the...

Key Insights Institutions' substantial holdings in Axogen implies that they have significant influence over the...

Dorman Products, Inc. ( NASDAQ:DORM ), is not the largest company out there, but it led the NASDAQGS gainers with a...

Key Insights Insiders appear to have a vested interest in Waton Financial's growth, as seen by their sizeable ownership...

Key Insights Tecnoglass' estimated fair value is US$47.53 based on 2 Stage Free Cash Flow to Equity Tecnoglass is...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

There wouldn't be many who think BARK, Inc.'s ( NYSE:BARK ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...

The FDA’s acceptance of Replimune Group’s resubmitted Biologics License Application for RP1, combined with nivolumab, has sparked renewed optimism among investors. This regulatory milestone follows months of addressing agency feedback and signals real progress for the company’s advanced melanoma program. See our latest analysis for Replimune Group. The FDA's green light for Replimune's RP1 application sent the share price soaring nearly 99% in a single day, erasing months of slow declines and...

As the U.S. stock market begins the week on a high note, buoyed by gains across major indices and ongoing developments in trade and inflation data, investors are keenly observing opportunities amid economic uncertainties like the prolonged government shutdown. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential for growth, making it crucial to consider factors such as financial health and market position when evaluating investment...

As of October 2025, the U.S. stock market has shown robust gains, with major indices such as the Nasdaq and S&P 500 closing higher amid a backdrop of ongoing government shutdowns and fluctuating commodity prices. In this environment, growth companies with substantial insider ownership can be particularly appealing to investors, as they often indicate strong management confidence and alignment with shareholder interests.

As the U.S. markets experience a strong start to the week, with major indices climbing over 1%, investors are keenly watching for corporate earnings and economic data that could influence Federal Reserve decisions on interest rates. In this environment of heightened market activity, dividend stocks remain an attractive option for those seeking steady income and potential growth, as they can offer stability amid broader market fluctuations.

On October 20, 2025, Safe Pro Group Inc. announced a private placement of 2,000,000 common shares at US$7 per share for gross proceeds of US$14,000,000, with Ondas Holdings Inc. as the lead new investor and expected closing on October 22, 2025, subject to standard conditions. In addition, Safe Pro Group recently filed a US$100 million shelf registration, opening the door to a broad range of potential future securities offerings that could support the company's funding needs. We'll explore...